Now for some evidence. Bold font added for emphasis.

http://www.ncbi.nlm.nih.gov/pubmed/20095393 !he influence of the original dipeptide drug noopept" #nown to possess nootrope" neuroprotector" and an$iol%tic properties" on the anticonvulsant activit% of the antiepileptic drug valproate has been studied on the model of cora&ole'induced convulsions in mice. Neither a single administration of noopept (0.5 mg/#g" i.p.) nor its repeated introduction in *0 or 35 da%s enhanced the convulsant effect of cora&ole" which is evidence that noopept alone does not possess anticonvulsant properties. +rolonged (five wee#s) preliminar% administration of noopept enhanced the anticonvulsant activit% of valproate. !his result ,ustifies the ,oint chronic administration of noopept in combination with valproate in order to potentiate the anticonvulsant effect of the latter drug. -n addition" the administration of noopept favorabl% influences the cognitive functions and suppresses the development of neurodegenerative processes.

http://www.ncbi.nlm.nih.gov/pubmed/*92.0/53 0e studied the effect of original dipeptide preparation Noopept (N'phen%lacet%l'1' prol%lgl%cine eth%l ester" 234'***) with nootropic and neuroprotective properties on the e$pression of m5N6 for neurotropic factors N27 and B8N7 in rat hippocampus. 9$pression of N27 and B8N7 m5N6 in the cerebral corte$ and hippocampus was studied b% Northern blot anal%sis. !a#ing into account the fact that pharmacological activit% of Noopept is reali&ed after both acute and chronic treatment" we studied the effect of single and long'term treatment (2/ da%s) with this drug. 9$pression of the studied neurotropic factors in the cerebral corte$ was below the control after single administration of Noopept" while chronic administration caused a slight increase in B8N7 e$pression. -n the hippocampus" e$pression of m5N6 for both neurotrophins increased after acute administration of Noopept. :hronic treatment with Noopept was not followed b% the development of tolerance" but even potentiated the neurotrophic effect. !hese changes probabl% pla% a role in neuronal restoration. 0e showed that the nootropic drug increases e$pression of neurotrophic factors in the hippocampus. ;ur results are consistent with the h%pothesis that neurotrophin s%nthesis in the hippocampus determines cognitive function" particularl% in consolidation and dela%ed memor% retrieval. +ublished data show that neurotrophic factor deficienc% in the hippocampus is observed not onl% in advanced 6l&heimer<s disease" but also at the stage of mild cognitive impairment (pre'disease state). -n light of this our findings suggest that Noopept holds much promise to prevent the development of 6l&heimer<s disease in patients with mild cognitive impairment. =oreover" therapeutic effectiveness of Noopept should be evaluated at the initial stage of 6l&heimer<s disease.

http://www.ncbi.nlm.nih.gov/pubmed/*259>52* !he paper describes pharmacological properties of the new nootropic drug noopept created using an original approach based on the imitation of a nonpeptide nootrope structure b% means of the short'peptide design. -n particular" the structure of p%racetam was designed using dipeptide nootropes. 9$perimental investigations of noopept (N' phen%lacet%l'1'pol%gl%cine eth%l ester) showed that the new drug e$ceeds p%racetam both with respect to the effective dose level (*000 times lower for noopept than for p%racetam) and in the spectrum of mnemotropic activit%. -n contrast to p%racetam facilitating onl% the earl% stages of the memor% process" noopept positivel% influences the memor% consolidation and retrieval steps as well. !he new drug produces an additional selective an$iol%tic action. !he pronounced neuroprotective effect of noopept was demonstrated both in vivo (in cases of various forms of brain ischemia) and in vitro (on various neuronal models). !he drug action is based on the antio$idant effect" the antiinflammator% action" and the abilit% to inhibit the neuroto$icit% of e$cess calcium and glutamate" and to improve the blood rheolog%. -t was established for the first time that the activit% of noopept is retained both upon parenteral introduction and upon peroral administration" which is a principal advantage of this proline'containing dipeptide over other" more comple$ peptides. !his propert% provided a basis for the development of a medicinal form of noopept for peroral usage. 6t present" noopept tablets (noopept 5 and *0 mg) are under clinical assessment as a means of treating cognitive deficienc% of cerebrovascular and post'traumatic origin.

!here are man% more studies which are all fairl% recent and ever% one of them shows remar#able promise for this nootropic. 6 good source for further information" with research citations" can be found here: http://www.whatarenootropics.com/noo...' list/noopept/ ? Note to moderators" the last lin# goes to a page that has a bu% noopept now lin#" so it might not be permitted here. 4orr% about that oversight. -t<s a good page otherwise.

5ead more: http://www.drugs'forum.com/forum/showthread.php@ tA*B2.53Ci$&&2rDwnd1m6